MENU
+Compare
DMAC
Stock ticker: NASDAQ
AS OF
Jul 21, 02:01 PM (EDT)
Price
$4.69
Change
+$0.51 (+12.20%)
Capitalization
179.25M

DMAC DiaMedica Therapeutics Forecast, Technical & Fundamental Analysis

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company... Show more

Industry: #Biotechnology
DMAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for DMAC with price predictions
Jul 18, 2025

DMAC in downward trend: price may drop because broke its higher Bollinger Band on July 15, 2025

DMAC broke above its upper Bollinger Band on July 15, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 47 similar instances where the stock broke above the upper band. In of the 47 cases the stock fell afterwards. This puts the odds of success at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 55 cases where DMAC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The 10-day moving average for DMAC crossed bearishly below the 50-day moving average on June 17, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 21 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DMAC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for DMAC entered a downward trend on July 14, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where DMAC's RSI Oscillator exited the oversold zone, of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on July 14, 2025. You may want to consider a long position or call options on DMAC as a result. In of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for DMAC just turned positive on July 09, 2025. Looking at past instances where DMAC's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .

DMAC moved above its 50-day moving average on July 14, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where DMAC advanced for three days, in of 256 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. DMAC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.280) is normal, around the industry mean (18.143). P/E Ratio (0.000) is within average values for comparable stocks, (58.647). DMAC's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.460). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (270.975).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DMAC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
DMAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

DMAC is expected to report earnings to rise 2.78% to -18 cents per share on August 06

DiaMedica Therapeutics DMAC Stock Earnings Reports
Q2'25
Est.
$-0.19
Q1'25
Beat
by $0.02
Q4'24
Missed
by $0.01
Q3'24
Beat
by $0.01
Q2'24
Beat
by $0.03
The last earnings report on May 13 showed earnings per share of -18 cents, beating the estimate of -20 cents. With 268.91K shares outstanding, the current market capitalization sits at 179.25M.
A.I. Advisor
published General Information

General Information

a developer of novel therapeutic compounds for diabetes and other diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
301 Carlson Parkway
Phone
+1 763 496-5454
Employees
19
Web
https://www.diamedica.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CRHKF3.31N/A
N/A
China Resources Beer Holdings Company Limited
WFRSF1.47N/A
N/A
West African Resources Ltd.
MRPT0.06N/A
N/A
MacReport.Net, Inc. (The)
FLMNY13.40N/A
N/A
Fielmann Group AG
ISVLF0.26-0.02
-7.95%
IMPACT Silver Corp.

DMAC and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, DMAC has been loosely correlated with WHWK. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if DMAC jumps, then WHWK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DMAC
1D Price
Change %
DMAC100%
+6.36%
WHWK - DMAC
46%
Loosely correlated
-2.70%
VICP - DMAC
33%
Poorly correlated
N/A
HUMA - DMAC
32%
Poorly correlated
-3.72%
ELDN - DMAC
30%
Poorly correlated
-1.33%
CYYNF - DMAC
30%
Poorly correlated
N/A
More